LGND Q3 2024 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$52M+57.6% YoY

Gross Profit

$39M75.9% margin

Operating Income

$3M6.1% margin

Net Income

-$7M-13.8% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

+24.8%

Cash Flow

Operating Cash Flow

$37M

Free Cash Flow

$22M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$955M

Total Liabilities

$114M

Stockholders' Equity

$841M

Cash & Equivalents

$64M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$52M	$33M	+57.6%
Gross Profit	$39M	$29M	+33.8%
Operating Income	$3M	$3M	+2.1%
Net Income	-$7M	-$10M	+30.2%

Revenue Segments

Royalty

$32M35%

Intangible Royalty Assets

$27M29%

Kyprolis

$12M13%

Material Sales, Captisol

$6M7%

Financial Royalty Assets

$5M6%

Rylaze

$4M4%

Teriparatide Injection

$2M3%

Royalty, Other

$2M2%

Evomela

$2M2%